{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '5.4.1.5', 'Visit 5 (Week 44)', 'The following assessments will be conducted at Visit 5 (Week 44):', 'Administer Patient Global Assessment of Disease Activity (VAS).', 'Administer Patient Assessment of Pain (VAS).', 'Administer HAQ-DI.', 'Perform joint counts (Independent Joint Assessment).', 'Assess Treatment Response', 'Assess AEs/SAEs and injection site reactions that have occurred since the previous', 'visit.', 'Administer Physician Global Assessment (VAS).', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Record weight.', 'Record vital signs.', 'Perform partial physical examination.', 'Collect sample to measure CRP level.', 'Measure ESR.', 'Collect samples for chemistry panel and hematology assessments.', 'Perform urine pregnancy test for females of childbearing potential only.', 'Collect and review Subject Diary.', 'Assess treatment compliance.', 'Allocate study treatment through the IWRS.', '- In addition to study treatment for Visit 5 (Week 44) administration, subjects will', 'receive 1 vial or 1 PFS of OKZ for each dose that is scheduled to be administered', 'prior to Visit 6 (Week 52).', 'Administer study treatment.', 'Amendment 2: 06 March 2019', '64', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '5.4.1.6', 'Visit 6 (Week 52)', 'The following assessments will be conducted at Visit 6 (Week 52):', 'Administer Patient Global Assessment of Disease Activity (VAS).', 'Administer Patient Assessment of Pain (VAS).', 'Administer HAQ-DI.', 'Administer SF-36, EQ-5D, FACIT-Fatigue, and WPS-RA.', 'Perform joint counts (Independent Joint Assessment).', 'Assess Treatment Response', 'Assess AEs/SAEs and injection site reactions that have occurred since the previous', 'visit.', 'Administer Physician Global Assessment (VAS).', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Administer TB risk questionnaire.', 'Record weight.', 'Record vital signs.', 'Perform complete physical examination.', 'Perform CV risk assessment.', 'Perform 12-lead ECG.', 'Perform chest X-ray.', '-', 'Chest X-ray need not be conducted if performed and evaluated within 8 weeks prior', 'to Visit 6 (Week 52), and if the films or images are available and included in the', \"subject's source documents.\", 'Measure ESR.', 'Collect sample to measure CRP level.', 'Collect samples for lipid panel.', 'Amendment 2: 06 March 2019', '65', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Collect samples for chemistry panel, hematology assessments, ANAs, and dsDNA', 'antibodies.', 'Collect sample for HbA 1c assessment (subjects with confirmed diabetes mellitus only).', 'Perform IGRA testing only for subjects who had a negative IGRA result at the', 'previous assessments (including Week 22 assessment of the core study) unless another', 'approach is required by local practice. If results are indeterminate, the IGRA can be', 'repeated once.', 'Collect sample for analysis of ADAs.', 'Perform urine pregnancy test for females of childbearing potential only.', 'Collect sample for urinalysis.', 'Collect and review Subject Diary.', 'Assess treatment compliance', 'Allocate study treatment through the IWRS.', '-', 'In addition to study treatment for Visit 6 (Week 52) administration, subjects will', 'receive 1 vial or 1 PFS of OKZ for each dose that is scheduled to be administered', 'prior to Visit 7 (Week 64).', 'Administer study treatment.', '5.4.1.7', 'Visit 7 (Week 64)', 'The following assessments will be conducted at Visit 7 (Week 64):', 'Administer Patient Global Assessment of Disease Activity (VAS).', 'Administer Patient Assessment of Pain (VAS).', 'Administer HAQ-DI.', 'Administer SF-36, EQ-5D, FACIT-Fatigue, and WPS-RA.', 'Perform joint counts (Independent Joint Assessment).', 'Assess Treatment Response', 'Assess AEs/SAEs and injection site reactions that have occurred since the previous', 'visit.', 'Amendment 2: 06 March 2019', '66', 'Confidential']\n\n###\n\n", "completion": "END"}